Clinical Trials Logo

ERa+ Breast Cancer clinical trials

View clinical trials related to ERa+ Breast Cancer.

Filter by:
  • None
  • Page 1

NCT ID: NCT04174352 Recruiting - ESR1 Gene Mutation Clinical Trials

FES Imaging to Optimize Tamoxifen for Metastatic Breast Cancer

Start date: October 20, 2020
Phase: Early Phase 1
Study type: Interventional

Despite broad advancements in endocrine therapy for ERα+ breast cancer, resistance ultimately develops. A common driver of resistance are known ESR1 mutations that lead to constitutively active receptor signaling and transcriptional regulation that is always "turned on" despite the absence of estrogen. Patients with ESR1 mutations are expected to have decreased binding affinity for tamoxifen and thus may be underdosed on standard therapy. [18F]-fluoroestradiol Positron Emission Tomography/Computed tomography (FES-PET/CT) imaging is a novel functional imaging technique that can non-invasively measure ERα expression and inhibition in metastatic ERα+ breast cancer. The proposed a pilot study uses FES-PET/CT imaging to measure ERα blockade to determine the optimal dose of tamoxifen in patients with ESR1 mutations.